Parison Amy sold $1K of EDIT

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Editas Medicine (EDIT) stock rose 7.2% in pre-market trading after Guggenheim upgraded it to Buy with a $5.00 price target, citing strong preclinical data for EDIT-401, its gene therapy for severe hypercholesterolemia. The move is company-specific, with broader markets trading lower. EDIT's 52-week range is $1.66 to $4.54.

Editas Medicine (NASDAQ:EDIT) aims to dose patients with its LDL gene-editing therapy, EDIT-401, in 2026, targeting a human-equivalent dose of 0.6 mg/kg. The Phase I/II study has two parts, with initial safety data expected in Q1 2025 and top-line data in 2027. The company has $212M in cash, expected to last until mid-2028, supporting the study's advancement. Editas estimates a U.S. market of 9-10M patients for its therapy.

Editas Medicine (NASDAQ:EDIT) plans to start a Phase 1 trial for its CRISPR-based cholesterol therapy, EDIT-401, in Australia this year. The trial aims to treat patients with heterozygous familial hypercholesterolemia. Preclinical data suggests a 15% allele edit could significantly lower cholesterol. The company has $212 million in cash and expects its runway to extend into mid-2028.

Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoprotei

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).